Summary

Eligibility
for people ages 65 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Sammy Elmariah, MD
Headshot of Sammy Elmariah
Sammy Elmariah

Description

Summary

This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.

Details

Keywords

Mitral Valve Regurgitation, surgical mitral valve repair, transcatheter edge-to-edge repair, Mitral Valve Insufficiency, Prolapse, Mitral valve repair

Eligibility

Locations

  • UCSF accepting new patients
    San Francisco California 94143 United States
  • Stanford University accepting new patients
    Stanford California 94305 United States

Lead Scientist at UCSF

  • Sammy Elmariah, MD
    Dr. Sammy Elmariah is an interventional cardiologist who specializes in caring for patients with heart valve disease, coronary artery disease, and adult congenital heart disease.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Annetine Gelijns
ID
NCT05051033
Study Type
Interventional
Participants
Expecting 450 study participants
Last Updated